Navigation Links
Pilot Therapeutics Announces New Executive Team with Extensive Experience Creating New Health and Nutrition Businesses
Date:10/19/2007

WINSTON-SALEM, N.C., Oct. 19 /PRNewswire/ -- Pilot Therapeutics Inc., a Nutritional Therapeutics Innovation Company, today announced the appointment of Ross Consaul as CEO and Keith Wakeman as President.

"Pilot has always had promising technology and patents in the food, medical food and dietary supplement areas with over 60 issued and pending patents. These new additions will unlock the potential to rapidly move our world class technologies and IP to the marketplace," said Dr. Floyd "Ski" Chilton, Founder and Chief Technology Officer of Pilot Therapeutics Inc.

Ross joins Pilot with over 20 years experience leading New Ventures, R&D, and New Product Development for large and small companies including Bayer, Kellogg, Pizza Hut and Kashi. He was most recently Nutrition General Manager for Bayer BioScience where he was responsible for identifying and creating new health and nutrition businesses for Bayer.

Keith brings over 20 years of management experience in the food and nutrition industry leading Marketing, Innovation and New Ventures organizations for major companies including Kellogg, Keebler and Nabisco. He was most recently President of Cherry Street Innovation LLC, an innovation company he founded to identify and develop new growth platforms through new ventures and brand innovation.

Former President Scott Derks will remain with Pilot as Vice President, Operations.

"Collectively, Ross and Keith have created new businesses generating nearly $3 billion revenue and bring tremendous experience in health and nutrition. We are delighted to welcome them to our team," said Chilton.

Pilot Therapeutics is a Nutritional Therapeutics Innovation Company dedicated to the prevention and treatment of chronic inflammatory diseases. Through its Functional Liponomics(TM) discovery platform, Pilot examines the influence of fatty acids on the expression of genes that control the inflammatory and allergic process. Utilizing this technology Pilot has developed a pipeline of medical foods for the prevention and treatment of numerous chronic inflammatory disorders in humans and animals. These innovative products are based on over 60 issued and pending domestic and international patents.

Pilot Therapeutics was founded by Chilton, professor of physiology and pharmacology at Wake Forest University School of Medicine. Chilton is also director of the Wake Forest and Brigham and Women's Program for Botanical Lipids which is supported by a $7.5 million grant from the National Center for Complementary and Alternative Medicine and the Office of Dietary Supplements.


'/>"/>
SOURCE Pilot Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. RFID pilot project aims to improve blood banks
2. Pilot fund brings capital to Eau Claire area innovations
3. National $100m pilot program to begin mapping cancer genome
4. Milwaukee health provider network pilots software plan
5. Gateway Technical College pilots IBM training program
6. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
7. Speaker announces business members of IT Task Force
8. Doyle announces technology tax credits for Berbee
9. Doyle announces new energy, global warming policies
10. Doyle announces $80M renewable energy strategy
11. GE announces first installation of Discovery VCT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the leading ... the world, is pleased to announce the 2nd annual Precision Medicine Virtual Conference. ... online-only conference focused on the development and advancements in precision medicine. , Precision ...
(Date:2/22/2017)... Feb. 22, 2017 Origin (Origin Agritech, LLC, a subsidiary ... seed provider, and Arcadia (Arcadia Biosciences, Inc., ... and commercializes agricultural productivity traits and nutritional products, today announced their ... product developed in China to ... ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... announced the addition of Tom Perkins as European director. Operating from Pennside’s Zurich ... to Pennside. , Perkins joins Pennside after more than a decade with ...
(Date:2/21/2017)... 2017 Synthetic Biologics, Inc. (NYSE MKT: SYN), ... to protect and restore the health of patients, intends to report ... 2016 on Thursday, March 2, 2017, and to host a conference ... for the call is as follows: U.S. (toll free): ... ...
Breaking Biology Technology:
(Date:2/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the LEERINK Partners 6th Annual Global Healthcare ... Wednesday, February 15, 2017 at 10 a.m. Eastern Time. ... can be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/2/2017)... 2, 2017  EyeLock LLC, a market leader of ... paper " What You Should Know About Biometrics in ... user authenticity is a growing concern. In traditional schemes, ... However, traditional authentication schemes such as username/password suffer from ... authentication offers an elegant solution to the problem of ...
Breaking Biology News(10 mins):